News

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Bechtel’s manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general contractor.

As Medicare Bridge participation surges, Novo Nordisk’s share of those new patients is drawing attention.

New pills, injections and maintenance regimens broaden patient choice while raising the durability test for market leaders.

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets

InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

The company continues to dominate the weight loss market.

Houston will produce Foundayo ingredients, linking manufacturing capacity directly to Lilly's planned global rollout.

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.

Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.

Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.

On September 22, AutoZone, Inc. (NYSE:AZO) reported results for its fourth quarter, which covered 16 weeks and ended August 29, 2026. The company delivered stronger-than-expected profits and the stock ended the session 3.26% higher. The company’s net sales increased 5.6% year-over-year to $6.6 billion, while operating profit rose 10.1% to $1.3 billion. Net income reached […]

Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.

Eli Lilly and Co.‘s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decision to cover obesity drugs. On Monday, Ricks said in an interview with CNBC that 70% of the...

The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.

Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

Medicare coverage opens the obesity pill market to millions more Americans.

Less-frequent injections could challenge chronic-treatment economics long before Viking reaches the market.

The company aims to launch more than five potential blockbuster drugs by 2030.

Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. This large Houston buildout for Foundayo is an important piece to weigh alongside the rest of our...

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.